In vitro Effects of alchoholic and aquatic Extract of Physalis alkekengi on proliferation of Trichomonas vaginalis

Document Type : Original Article


1 M.Sc., Department of Animal Biology (Developmental cellular), Faculty of Sciences, Islamic Azad University, Karaj Branch, Karaj, Iran.

2 Assistant Professor, Animal Biology (Developmental cellular), Faculty of Sciences, Islamic Azad University, Karaj Branch, Karaj, Iran.


Introduction: Trichomonas vaginalis is a parasite from flagellate which leads to trichomomal vaginitis. Also, it can be responsible for various complications such as discharge, painful urination, genital irritation, discomfort after intercourse, premature rupture of membranes, and preterm labor. Metronidazole is a selected drug for treatment of the disease that carcinogenesis effects of this drug and also resistance of this parasite toward metronidazole have been reported in recent years. Since physalis alkekengi plant has been applied for treatment of gastrointestinal diseases, hepatitis, viral, gonorrhea, gout, diabetes, and sore throat, therefore, this study was performed with aim to determine in vitro effects of aqueous and alcoholic extracts of physalis alkekengi on Trichomonas vaginalis.
Methods: This … study was performed in 2015 to assess the anti-parasite effects of physalis alkekengi on Trichomonas vaginalis. At first, the aqueous and alcoholic extracts were prepared and proliferation of parasites in TYM Diamond culture medium was performed. The concentrations of extract were: 8000, 4000, 2000, 1000, 500 and 250 µg/ml. The proliferation was evaluated at 24, 48 and 72 hours compared to control (metronidazole 50 µg/ml) group. In all of cases, the number of live and dead parasites was counted with Trypan blue and Neubauer slide. Data was analyzed by software SPSS (version 18) and one-way variance analysis. PResults: The aqueous and alcoholic extracts had significant inhibitory effects on Trichomonas vaginalis parasite proliferation (P<0.01). %IC50 aqueous and alcoholic extracts of physalis alkekengi at 24 h in concentration of 8000 and 4000 µg/ml were 100% compared to the control group (metronidazole). Alcoholic extract of the physalis alkekengi plant showed 100% inhibitory effect in concentration of 2000 µg/ml at 48 hours after exposure to the parasite. While, the aqueous extract in the same time at 8000µg/ml was effective.
Conclusion: After evaluation of effectiveness mechanism, the aqueous and alcoholic extracts of the physalis alkekengi plant can be alternative treatment potential in cases of resistance to metronidazole.


  1. Soheili F, Alizadeh S, Hassani M, Bastami P. The pathologic assessment of breast masses, before and after menopause. Iran Obstet Gynecol Infertil 2013; 16(68):21-7. (Persian).
  2. Karimi A, Moradi Z, Sayehmiri K, Delpisheh A, Sayehmiri F. Investigation of 1 to 10-year survival of breast cancer in Iranian women: a systematic review and meta-analysis. Iran Obstet Gynecol Infertil 2016; 19(22):17-25. (Persian).
  3. Adjogatse D, Thanopoulou E, Okines A, Thillai K, Tasker F, Johnston SR, et al. Febrile neutropaenia and chemotherapy discontinuation in women aged 70 years or older receiving adjuvant chemotherapy for early breast cancer. Clin Oncol 2014; 26(11):692-6.
  4. Jensen JD, Cold S, Nielsen MH, Jylling AM, Søe KL, Larsen LB, et al. Trends in breast cancer in the elderly in Denmark, 1980-2012. Acta Oncol 2016; 55(Suppl 1):59-64.
  5. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000; 18(8):1709-17.
  6. Litvak DA, Arora R. Treatment of elderly breast cancer patients in a community hospital setting. Arch Surg 2006; 141(10):985-90.
  7. de Glas NA, Kiderlen M, de Craen AJ, Hamaker ME, Portielje JE, van de Velde CJ, et al. Assessing treatment effects in older breast cancer patients: systematic review of observational research methods. Cancer Treat Rev 2015; 41(3):254-61.
  8. Benevento R, Santoriello A, Gambardella A, Mocerino C, Perna G, Gambardella C, et al. The role of sentinel node biopsy (SNB) in elderly breast cancer patients. BMC Geriat 2010; 10(1):A3.
  9. Valassiadou K, Morgan DA, Robertson JF, Pinder SE, Cheung KL. Successful management of elderly breast cancer patients treated without radiotherapy. World J Surg Oncol 2007; 5:62.
  10. Li JJ, Yu KD, Di GH, Shao ZM. Clinicopathological features and treatment sensitivity of elderly Chinese breast cancer patients. Oncol Lett 2010; 1(6):1037-43.
  11. Rocco N, Iannone L, Rispoli C, De Vito D, Accurso A. Early breast cancer in elderly women: surgery or primary endocrine therapy? BMC Geriat 2010; 10(1):A31.
  12. Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. J Cancer Epidemiol 2013; 2013:893104.
  13. Dimitrakopoulos F, Kottorou A, Antonacopoulou AG, Makatsoris T, Kalofonos HP. Early-stage breast cancer in the elderly: confronting an old clinical problem. J Breast Cancer 2015; 18(3):207-17.
  14. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007; 13(4):383-91.
  15. Villari SA, Famà F, Scarfò P, Pollicino A, Florio MG. Tailored surgery in elderly patients with breast cancer: our experience. BMC Geriat 2010; 10(Suppl 1):A38.
  16. Wang H, Singh AP, Luce SA, Go AR. Breast cancer treatment practices in elderly women in a community hospital. Int J Breast Cancer 2011; 2011:467906.

Angarita FA, Chesney T, Elser C, Mulligan AM, McCready DR, Escallon J. Treatment patterns of elderly breast cancer patients at two Canadian cancer centers. Eur J Surg Oncol 2015; 41(5):625-34.